Dyne Therapeutics grants CMO Douglas Kerr 8,000 restricted stock units

DYN•2026-10-22

Dyne Therapeutics awarded CMO Douglas Kerr 8,000 common stock shares on October 20, 2026, and options to buy 12,000 shares at $16.27 each, expiring October 19, 2036.

1. Kerr receives equity awards

Dyne Therapeutics awarded R&D head and CMO Douglas Kerr 8,000 common stock shares on October 20, 2026. Kerr also received options to buy 12,000 common stock shares at an exercise price of $16.27 per share; the options expire on October 19, 2036.

Sources

Dyne Therapeutics grants CMO Douglas Kerr 8,000 restricted stock units

Sec

Dyne Therapeutics grants CMO Douglas Kerr 8,000 restricted stock units

1. Kerr receives equity awards

Related News

Bank of America reports disposal of $972.8946 in Nuveen Municipal Credit Opportunities Fund common shares

Chemung Financial Q3 net income beats, helped by commercial loan growth

Net Power extends deadline to proceed with Saulsbury construction contract to March 31, 2027

Sources

Dyne Therapeutics grants CMO Douglas Kerr 8,000 restricted stock units

BNY Mellon High Yield Strategies Fund declares monthly dividend of $0.0175 per share

Live Nation Entertainment publishes update to financial calendar